NEW YORK, July 7, 2026, 12:07 PM EDT
- ClearOne, Inc. NASDAQ:CLRO last changed hands up 48% at $10.36 after a July 6 SEC filing offering more specifics on the Cortigent merger.
- Trading volume hit 41.4 million shares, close to 48 times the listed float of 0.87 million shares.
- Current ClearOne shareholders would get around 12.7% to 14.4% of the merged company if the transaction closes.
- The deal still needs shareholder signoff, Nasdaq listing approval and between $10 million and $15 million in financing.
ClearOne, Inc. NASDAQ:CLRO shares surged in active midday trade Tuesday, as the thinly traded Nasdaq stock posted one of the session’s bigger micro-cap swings. The move came after a new company filing revealed share counts and financing details tied to ClearOne’s planned merger with Cortigent, Inc.
Shares last changed hands at $10.36, up $3.36 from Monday’s finish, swinging between $6.30 and $12.14 during the session. About 41.4 million shares traded. For comparison, ClearOne lists 0.87 million shares in the float and 2.68 million shares outstanding.
| Market snapshot July 7 | Last price | Move | Volume |
|---|---|---|---|
| ClearOne NASDAQ:CLRO surged | $10.36 | up 48.0% | 41.4 mln |
| Vivani Medical NASDAQ:VANI added | $1.30 | 0.8% higher | 9.7 mln |
| Invesco QQQ Trust NASDAQ:QQQ slid | $708.39 | down 2.0% | 20.2 mln |
What stands out is the churn. ClearOne turned over roughly 15.5 times its May 15 share count and close to 48 times its float by late morning. The run-up is happening through a tight supply, and with the deal coming, a much bigger share count is expected after closing.
ClearOne said in a July 6 Form 8-K that it reached a deal July 1 to merge its subsidiary into Cortigent, which is part of Vivani Medical, Inc. NASDAQ:VANI. Cortigent will become a wholly owned ClearOne unit. Vivani is set to get 12.5 million ClearOne shares in the transaction.
Vivani’s filing from July 7 said the funding for the deal needs to bring in $10 million to $15 million. The plan would issue 2.5 million to 5.0 million units, each made up of a ClearOne share and a warrant to buy a ClearOne share at $10.00 for six months.
| Deal item from filings | Share impact |
|---|---|
| ClearOne had 2.675 mln shares out as of May 15 | 2.675 mln |
| Shares going to Vivani for Cortigent | 12.500 mln |
| Shares for financing | 2.500 mln-5.000 mln |
| Shares for advisers or service providers, according to ClearOne | up to 0.855 mln |
| Cortigent-linked stock options, per ClearOne | up to 1.400 mln |
Basing on the May 15 share count, filings suggest about 18.5 million to 21 million shares outstanding before factoring in Cortigent options and financing warrants. At $10.36 a share, that puts the implied equity value between $192 million and $218 million on those figures—well above ClearOne’s current $28.7 million market cap before any new share issuance. SEC SEC
This is the trade-off for the stock. ClearOne’s rally boosts the share price ahead of the financing set to close with the merger. The $10.00 financing warrants are also close to the money after the latest price.
ClearOne said July 2 that Vivani will end up with between 59.4% and 67.5% of the merged company, and ClearOne shareholders would own around 12.7% to 14.4%. If the deal is completed, ClearOne plans to change its name to Cortigent Holdings, Inc. and will trade as “CRGT” on Nasdaq. ClearOne
ClearOne board chair Eric Robinson said in the statement that Cortigent’s mission “is compelling.” He said the planned financing should give the combined firm “a strong foundation.” ClearOne
Vivani CEO Adam Mendelsohn said the deal is the “planned merger and financing of Cortigent.” Cortigent’s chief, Jonathan Adams, said the financing “will enable accelerated development” of products including the Orion artificial vision device and another aimed at restoring arm and hand mobility after stroke. BioSpace
The filing limits one risk but some remain. ClearOne said holders of at least 50.1% of its common stock have signed voting support agreements. The deal still needs shareholder approval, completed financing, ongoing Nasdaq listing for existing shares, Nasdaq approval for new shares, and an effective Form S-1.
ClearOne has stopped acting like a typical conferencing-products stock. Last year it said it sold assets to Biamp Systems, but it kept its public-company features—transfer records, registrations, ticker, and listing. Then-CEO Derek Graham said ClearOne would “continue to exist as a public company” even after the asset sale. ClearOne
